Immunosuppression for pancreas transplantation with an emphasis on antibody induction strategies: Review and perspective

Expert Review of Clinical Immunology

Volumn 10, Issue 1, 2014, Pages 117-132

  Stratta, Robert J ^a   Farney, Alan C ^a   Rogers, Jeffrey ^a   Orlando, Giuseppe ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

alemtuzumab; antibody induction; basiliximab; calcineurin inhibitors; diabetes mellitus; mycophenolate; rabbit antithymocyte globulin; sirolimus; steroid withdrawal; tacrolimus

Indexed keywords

ALEMTUZUMAB; ANTIBODY; BASILIXIMAB; C PEPTIDE; CALCINEURIN INHIBITOR; COMPLEMENT COMPONENT C4D; CORTICOSTEROID; DACLIZUMAB; EVEROLIMUS; HLA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADVERSE OUTCOME; ANTIBODY INDUCTION THERAPY; ANTIBODY MEDIATED REJECTION; CASE MIX; CYTOMEGALOVIRUS INFECTION; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LONG TERM SURVIVAL; MAINTENANCE THERAPY; MONOTHERAPY; NEPHROTOXICITY; ORGAN DONOR; PANCREAS TRANSPLANTATION; QUALITY OF LIFE; REVIEW; RISK FACTOR; TREATMENT WITHDRAWAL;

ALLOGRAFTS; ANIMALS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; PANCREAS TRANSPLANTATION;

EID: 84893130292     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.853616     Document Type: Review

References (80)

1. Margreiter C, Pratschke J, Margreiter R. Immunological monitoring after pancreas transplantation. Curr. Opin. Organ. Transplant.18(1), 71-75 (2013).
2. Kudva YC, Erickson JR, Parsaik A et al. Comprehensive immune monitoring reveals profound immunological changes in pancreas after kidney (PAK) transplant recipients. Human Immunol. 74(6), 738-745 (2013).
3. Knight RJ, Kerman RH, McKissick E et al. Selective corticosteroid and calcineurin-inhibitor withdrawal after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy. Clin.Transplant. 22(5), 645-650 (2008).
4. Thai NL, Blisard D, Tom K et al. Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: correlation between low T-cell responses and infection. Transplantation 82(12), 1649-1652 (2006).
5. Gruessner AC. 2011 update on pancreas transplantation: comprehensive trend analysis of25,000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry (IPTR). Rev. Diab. Stud. 8(1), 6-16 (2011).
6. Opelz G. Presidents address. The Transplantation Society - Berlin 2012. Transplantation 95(1), 4-7 (2013).
7. Kandaswamy R, Stock PG, Skeans MA et al. OPTN/SRTR 2011 annual data report: pancreas. Am. J. Transplant. 13(Suppl. 1) (1), 47-72 (2013).
8. Egidi FM. Management of hyperglycemia after pancreas transplantation: are new immunosuppressants the answer? Drugs 65(2), 153-166 (2005).
9. Schmied BM, Muller SA, Mehrabi A et al. Immunosuppressive standards in simultaneous kidney-pancreas transplantation. Clin. Transplant. 20(Suppl. 17) (6), 44-50 (2006).
10. Axelrod D, Kaufman DB. Novel immunosuppression in pancreas transplantation and outcomes. Curr. Opin. Organ. Transplant. 12(1), 77-81 (2007).
11. Singh RP, Stratta RJ. Advances in immunosuppression for pancreas transplantation. Curr.Opin. Organ. Transplant. 13(1), 79-84 (2008).
12. Mineo D, Sageshima J, Burke GW, Ricordi C. Minimization and withdrawal of steroids in pancreas transplantation. Transplant. Int. 22(1), 20-37 (2008).
13. Cantarovich D, Vistoli F. Minimization protocols in pancreas transplantation. Transplant. Int. 22(1), 61-68 (2009).
14. Heilman RL, Mazur MJ, Reddy KS. Immunosuppression in simultaneous kidney-pancreas transplantation. Drugs 70(7), 793-804 (2010).
15. Rangel EB. The metabolic and toxicological considerations for immunosuppressive drugs during pancreas transplantation. Expert Opin. Drug Metab. Toxicol. 8(12), 1531-1548 (2012).
16. Kimelman M, Brandacher G. Trends in immunosuppression after pancreas transplantation: what is in the pipeline? Curr. Opin. Organ Transplant. 18(1), 76-82 (2013).
17. Niederhaus SV, Kaufman DB, Odorico JS. Induction therapy in pancreas transplantation. Transplant. Int. 26(7), 704-714 (2013).
18. Zachariah M, Gregg A, Schold J, Magliocca J, Kayler LK. Alemtuzumab induction in simultaneous pancreas and kidney transplantation. Clin. Transplant. 27(5), 693-700(2013).
19. Dong M, Parsaik AK, Kremers W et al. Acute pancreas allograft rejection is associated with increased risk of graft failure in pancreas transplantation. Am. J. Transplant. 13(4), 1019-1025(2013).
20. Reddy KS, Davies D, Ormond D et al. Impact of acute rejection episodes on long-term graft survival following simultaneous kidney-pancreas transplantation. Am. J. Transplant. 3(4), 439-444 (2003).
21. Kaplan B, West-Thielke P, Herren H et al. Reported isolated pancreas rejection is associated with poor kidney outcomes in recipients of a simultaneous pancreas kidney transplant. Transplantation 86(9), 1229-1233 (2008).
22. Arbogast H, Malaise J, Illner WD et al. Rejection after simultaneous pancreas-kidney transplantation. Nephrol. Dial. Transplant. 20(Suppl. 2), ii11-ii17 (2005).
23. Humar A, Khwaja K, Ramcharan T et al. Chronic rejection: the next major challenge for pancreas transplant recipients. Transplantation 76(6), 918-923 (2003).
24. Troxell ML, Koslin DB, Norman D et al. Pancreas allograft rejection: analysis of concurrent renal allograft biopsies and posttherapy follow-up biopsies. Transplantation 90(1),75-84 (2010).
25. Gruessner RWG, Sutherland D, Kandaswamy R et al. Over 500 solitary pancreas transplants in nonuremic patients with brittle diabetes mellitus. Transplantation 85(1), 42-47(2008).
26. Egidi MF, Lin A, Bratton CF, Baliga PK. Prevention and management of hyperglycemia after pancreas transplantation. Curr. Opin. Organ Transplant. 13(1), 72-78 (2008).
27. Fridell JA, Agarwal A, Powelson JA et al. Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosuppression. Transplantation 82(3), 389-92 (2006).
28. Vessal G, Wiland AM, Philosophe B et al. Early steroid withdrawal in solitary pancreas transplantation results in equivalent graft and patient survival compared with maintenance steroid therapy. Clin. Transplant. 21(4), 491-97 (2007).
29. Kandula P, Fridell J, Taber TE et al. Impact of tacrolimus-sirolimus maintenance immunosuppression on proteinuria and kidney function in pancreas transplant alone recipients. Transplantation 94(9), 94-99 (2012).
30. Dean PG, Kudva YC, Larson TS et al. Post transplant diabetes mellitus after pancreas transplantation. Am. J. Transplant. 8(1), 175-182 (2008).
31. Neidlinger N, Singh N, Klein C et al. Incidence of and risk factors for posttransplant diabetes mellitus after pancreas transplantation. Am. J. Transplant. 10(2), 398-406 (2010).
32. Gaber LW, Egidi MF, Gaber AO. An ideal nondiabetogenic, nonnephrotoxicimmunosuppressive protocols for pancreas transplantation. Curr. Opin. Organ Transplant. 8(2),186-189 (2003).
33. Burke GW, Vendrame F, Pileggi A et al. Recurrence of autoimmunity following pancreastransplantation. Curr. Diab. Rep. 11(5), 413-419 (2011).
34. Fioretto P, Steffes MW, Mihatsch MJ et al. Cyclosporine-associated lesions in native kidneys of diabetic pancreas transplant recipients. Kidney Int. 48(2), 489-495 (1995).
35. Fioretto P, Najafian B, Sutherland DER, Mauer M. Tacrolimus and cyclosporinenephrotoxicity in native kidneys of pancreas transplant recipients. Clin. J. Am. Soc. Nephrol. 6(1),101-106 (2011).
36. Rogers J, Farney AC, Al-Geizawi S et al. Pancreas transplantation: lessons learned from adecade of experience at Wake Forest Baptist Medical Center. Rev. Diabet. Stud. 8(1), 17-27(2011).
37. Drachenberg CB, Odorico J, Demetris AJ et al. Banff schema for grading pancreas allograftrejection: working proposal by a multi-disciplinary international consensus panel. Am. J. Transplant. 8(6), 1237-1249 (2008).
38. Drachenberg CB, Torrealba JR, Nankivell BJ et al. Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts - updated Banff grading schema. Am. J. Transplant. 11(9), 1792-1802 (2011).
39. Stratta RJ, Alloway RR, Lo A et al. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study. Transplantation 75(8), 1260-1266 (2003).
40. Stratta RJ, Alloway RR, Lo A, Hodge EE. A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: results at 3 years. Transplant. Proc. 37(8), 3531-3534 (2005).
41. Kaufman DB, Burke GW III, Bruce DS et al. Prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation. Am. J. Transplant. 3(7), 855-864 (2003).
42. Burke GW III, Kaufman DB, Millis JM et al. Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: three-year results. Transplantation 77(8), 1269-1275 (2004).
43. Zhang R, Florman S, Devidoss S et al. A comparison of long-term survivals of simultaneous pancreas-kidney transplant between African American and Caucasian recipients with basiliximab induction therapy. Am. J. Transplant. 7(7), 1815-1821 (2007).
44. Zhang R, Florman S, Devidoss S et al. The long-term survival of simultaneous pancreas and kidney transplant with basiliximab induction therapy. Clin. Transplant. 21(5), 583-589 (2007).
45. Becker LE, Nogueira VA, Abensur MP et al. No induction versus anti-IL2R induction therapy in simultaneous kidney pancreas transplantation: a comparative analysis. Transplant. Proc. 38(6), 1933-1936 (2006).
46. Kaufman DB, Leventhal JR, Koffron AJ et al. A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppression protocols. Tacrolimus/ mycophenolatemofetil versus tacrolimus/sirolimus. Transplantation 73(2), 169-177 (2002).
47. Axelrod D, Leventhal JR, Gallon LG et al. Reduction of CMV disease with steroid-free immunosuppression in simultaneous pancreas-kidney transplant recipients. Am. J. Transplant.5(6), 1423-1429 (2005).
48. Rajab A, Pelletier RP, Ferguson RM et al. Steroid-free maintenance immunosuppression with rapamune and low-dose neural in pancreas transplant recipients. Transplantation 84(9), 1131-1137 (2007).
49. Bazerbachi F, Selzner M, Boehnert MU et al. Thymoglobulin versus basiliximab induction therapy for simultaneous kidney-pancreas transplantation: impact on rejection, graft function, and long-term outcome. Transplantation 92(9), 1039-1043 (2011).
50. Magliocca JF, Odorico JS, Pirsch JD et al. A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation. Am. J. Transplant. 8(8), 1702-1710 (2008).
51. Pascual J, Pirsch JD, Odorico JS et al. Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. Transplantation 87(1), 125-132 (2009).
52. Stratta RJ, Lo A, Shokouh-Amiri MH et al. Improving results in solitary pancreas transplantation with portal-enteric drainage, thymoglobulin induction, and tacrolimus/ mycophenolate mofetil-based immunosuppression. Transplant. Int. 16(3), 154-160 (2003).
53. Freise CE, Kang SM, Feng S et al. Excellent short-term results with steroid-free maintenance immunosuppression in low-risk simultaneous pancreas-kidney transplantation. Arch. Surg. 138(10), 1121-1125 (2003).
54. Aoun M, Eschewege P, Hamoudi Y et al. Very early steroid withdrawal in simultaneous pancreas-kidney transplants. Nephrol. Dial. Transplant. 22(3), 899-905 (2007).
55. Bazerbachi F, Selzner M, Marques MA et al. Pancreas-after-kidney versus synchronous pancreas-kidney transplantation:comparison of intermediate-term results. Transplantation 95(3), 489-494 (2013).
56. Knight RJ, Kerman RH, Zela S et al. Pancreas transplantation utilizing thymoglobulin, sirolimus, and cyclosporine. Transplantation 81(8), 1101-1105 (2006).
57. Knight RJ, Podder H, Kerman RH et al. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation. Transplantation 89(6), 727-732 (2010).
58. Gallon LG, Winoto J, Chhabra D et al. Long-term renal transplant function in recipients of simultaneous kidney and pancreas transplant maintained with twoprednisone-free maintenance immunosuppressive combinations: Tacrolimus/mycophenolatemofetil versus tacrolimus/sirolimus. Transplantation 83(10), 1324-1329 (2007).
59. Bechstein WO, Malaise J, Saudek F et al. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: 1-year results of a large multicenter trial. Transplantation 77(8), 1221-1228 (2004).
60. Saudek F, Malaise J, Boucek P et al. Efficacy and safety of tacrolimus compared with ciclosporinmicroemulsion in primary SPK transplantation: 3-year results of the Euro-SPK 001 trial. Nephrol. Dial. Transplant. 29(Suppl. 2) (2), ii3-ii10 (2005).
61. Cantarovich D, Karam G, Hourmant M et al. Steroid avoidance versus steroid withdrawal after simultaneous pancreas-kidney transplantation. Am. J. Transplant. 5(6), 1332-1338 (2005).
62. Ciancio G, Sageshima J, Chen L et al. Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized single-center trial at years. Am. J. Transplant.12(12), 3363-3376 (2012).
63. Trofe J, Stratta RJ, Egidi MF et al. Thymoglobulin for induction or rejection therapy in pancreas allograft recipients:a single centre experience. Clin. Transplant. 16(Suppl. 7)(5), 34-44 (2002).
64. Issa N, Amer H, Dean PG et al. Postransplantlymphoproliferative disorder following pancreas transplantation. Am. J. Transplant. 9(8), 1894-1902 (2009).
65. Dawson KL, Patel SJ, Xu J et al. Effect of immunosuppression for first kidney or kidney/pancreas transplant on sensitization at the time of second transplant. Transplantation 91(7), 751-756 (2011).
66. Schulz T, Flecken M, Kapischke M, Busing M. Single-shot antithymocyte globulin and daclizumab induction in simultaneous pancreas and kidney transplant recipient:three-year results. Transplant. Proc. 37(4), 1818-1820 (2005).
67. Gruessner RWG, Kandaswamy R, Humar A et al. Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation. Transplantation 79(9), 1184-1189 (2005).
68. Thai NL, Khan A, Tom K et al. Alemtuzumab induction and tacrolimusmonotherapy in pancreas transplantation:one- and two-year outcomes. Transplantation 82(12), 1621-1624 (2006).
69. Boesmueller C, Oellinger R, Sieb M et al. Tacrolimusmonotherapy followingalemtuzumab induction in combined kidney-pancreas transplantation: results of a prospectiverandomized trial. Ann. Transplant.17(4), 45-51(2012).
70. Muthusamy ASR, Vaidya AC, Sinha S et al. Alemtuzumab induction and steroid free maintenance immunosuppression in pancreas transplantation. Am. J. Transplant. 8(10), 2126-2131 (2008).
71. Uemura T, Ramprasad V, Matsushima K et al. Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation. Transplantation 92(6), 678-685 (2011).
72. Clatworthy MR, Sivaprakasam R, Butler AJ et al. Subcutaneous administration of alemtuzumab in simultaneous pancreas-kidney transplantation. Transplantation 84(12), 1563-1567 (2007).
73. Kaufman DK, Leventhal JR, Gallon LG, Parker MA. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results. Am. J. Transplant. 6(2), 331-339 (2006).
74. Farney AC, Doares W, Rogers J et al. A randomized trial of alemtuzumab versusantithymocyte globulin induction in renal and pancreas transplantation. Transplantation 88(6),810-819 (2009).
75. Reddy KS, Devarapalli Y, Mazur M et al. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation:comparison to induction with antithymocyte globulin. Transplant. Proc. 42(6), 2006-2008 (2010).
76. Rangel EB, Malheiros DMAC, Ribiero de Castro MC et al. Antibody-mediated rejection (AMR) after pancreas and pancreas-kidney transplantation. Transplant. Int. 23(6), 602-610 (2010).
77. Mujtaba MA, Fridell JA, Higgins N et al. Early findings of prospective anti-HLA donor specific antibodies monitoring study in pancreas transplantation: Indiana university health experience. Clin. Transplant. 26(5), e492-e499 (2012).
78. Cantarovich D, De Amicis S, Akl A et al. Posttransplant donor-specific anti- HLA antibodies negatively impact pancreas transplantation outcome. Am. J. Transplant. 11(12), 2737-2746 (2011).
79. Papadimitriou JC, Drachenberg CB. Distinctive morphological features of antibody-mediated and T-cell-mediated acute rejection in pancreas allograft biopsies. Curr. Opin. Organ Transplant. 17(1), 93-99 (2012).
80. de Kort H, Roulosse C, Bajema IM, Drachenberg CB. Pancreas transplantation, antibodies and rejection: where do we stand? Curr. Opin. Organ. Transplant. 18(3), 337-344 (2013).